Edition:
United States

Agios Pharmaceuticals Inc (AGIO.OQ)

AGIO.OQ on NASDAQ Stock Exchange Global Select Market

69.64USD
16 Nov 2018
Change (% chg)

$2.37 (+3.52%)
Prev Close
$67.27
Open
$66.83
Day's High
$70.70
Day's Low
$66.83
Volume
246,561
Avg. Vol
164,257
52-wk High
$99.77
52-wk Low
$51.66

Latest Key Developments (Source: Significant Developments)

Agios Reports Third Quarter 2018 Financial Results
Thursday, 1 Nov 2018 07:00am EDT 

Nov 1 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.QTRLY REVENUE $15.2 MILLION VERSUS 11.4 MILLION.QTRLY LOSS PER SHARE $1.63.Q3 EARNINGS PER SHARE VIEW $-1.62 -- THOMSON REUTERS I/B/E/S.Q3 REVENUE VIEW $19.1 MILLION -- THOMSON REUTERS I/B/E/S.CURRENT CASH POSITION WILL ENABLE COMPANY TO FUND OPERATING. EXPENSES AND CAPEX THROUGH AT LEAST END OF 2020.  Full Article

Agios Reports Qtrly Loss Per Share $1.81
Wednesday, 14 Feb 2018 07:01am EST 

Feb 14 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.QTRLY LOSS PER SHARE $1.81.QTRLY TOTAL REVENUE $9.8 MILLION VERSUS $22.6 MILLION.Q4 EARNINGS PER SHARE VIEW $-1.66 -- THOMSON REUTERS I/B/E/S.AGIOS PHARMACEUTICALS - SEES CASH, CASH EQUIVALENTS AS OF DEC 31, 2017 ENABLING CO TO FUND EXPENSES, CAPEX REQUIREMENTS THROUGH AT LEAST END OF 2020.  Full Article

Agios prices offering of 7.09 mln shares at $67 per share
Thursday, 18 Jan 2018 08:43pm EST 

Jan 18 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS ANNOUNCES PRICING OF $475 MILLION PUBLIC OFFERING OF COMMON STOCK.AGIOS PHARMACEUTICALS - ‍IT HAS PRICED AN UNDERWRITTEN PUBLIC OFFERING OF 7.09 MILLION SHARES OF COMMON STOCK AT A PRICE TO PUBLIC OF $67.00 PER SHARE​.  Full Article

Agios Outlines Key 2018 Priorities Expanding Clinical And Research Programs To Drive Long Term Value
Monday, 8 Jan 2018 07:01am EST 

Jan 8 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS OUTLINES KEY 2018 PRIORITIES EXPANDING CLINICAL AND RESEARCH PROGRAMS TO DRIVE LONG TERM VALUE.AGIOS PHARMACEUTICALS INC - SEVENTH IND SUBMISSION FOR A DHODH INHIBITOR FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES EXPECTED IN 4Q 2018.AGIOS - 2017 YEAR END CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES OF $568M FUNDS EXPANDED CLINICAL & RESEARCH PROGRAMS THROUGH END OF 3Q 2019.AGIOS PHARMACEUTICALS INC - TWO PIVOTAL TRIALS IN PYRUVATE KINASE DEFICIENCY WITH AG-348, ACTIVATE-T TO INITIATE IN 1Q 2018 AND ACTIVATE IN 2Q 2018.AGIOS PHARMACEUTICALS INC - PHASE 2 PROOF OF CONCEPT TRIAL OF AG-348 IN THALASSEMIA PLANNED FOR 4Q 2018.AGIOS PHARMACEUTICALS INC - MAT2A INHIBITOR AG-270 EXPECTED TO ENTER PHASE 1 DOSE-ESCALATION TRIAL IN MTAP-DELETED TUMORS IN 1Q 2018.  Full Article

Agios Submits New Drug Application To The FDA For Ivosidenib
Tuesday, 26 Dec 2017 07:30am EST 

Dec 26 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS SUBMITS NEW DRUG APPLICATION TO THE FDA FOR IVOSIDENIB FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY AML AND AN IDH1 MUTATION.AGIOS PHARMACEUTICALS INC - EXPECTS TO INITIATE PHASE 1 TRIAL FOR AG-270 IN Q1 OF 2018.AGIOS PHARMACEUTICALS INC - ‍ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR AG-270 TARGETING MTAP-DELETED TUMORS​.  Full Article

Agios Pharmaceuticals Files For Potential Mixed Shelf Offering
Friday, 8 Dec 2017 04:14pm EST 

Dec 8 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS PHARMACEUTICALS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.  Full Article

Agios presents updated phase 1 data from dose expansion cohort of ivosidenib
Friday, 17 Nov 2017 07:05am EST 

Nov 17 (Reuters) - Agios Pharmaceuticals Inc :Agios presents updated phase 1 data from dose expansion cohort of ivosidenib (AG-120) in patients with IDH1 mutant positive glioma.Agios Pharmaceuticals Inc - ‍ivosidenib well-tolerated in patients with low grade glioma​.Agios Pharmaceuticals Inc - ‍additional preclinical data demonstrate that ivosidenib and AG-881 suppress 2-HG levels in brain tumor mouse models​.Agios Pharmaceuticals Inc - ‍there were 5 patients with serious adverse events (SAE) and all were deemed unrelated to study treatment​.Agios Pharmaceuticals - ‍preliminary data suggest that both molecules suppress oncometabolite D-2-hydroxyglutarate in an orthotopic brain tumor model​.Agios Pharmaceuticals - study ‍to refine imaging methodology, assess biological effects of IDH inhibitors in perioperative study planned for H1 of 2018​.  Full Article

Agios reports Q3 revenue $11.4 million
Wednesday, 1 Nov 2017 07:00am EDT 

Nov 1 (Reuters) - Agios Pharmaceuticals Inc :Agios reports third quarter 2017 financial results.Q3 revenue $11.4 million versus I/B/E/S view $9.8 million.Agios Pharmaceuticals Inc - Qtrly ‍net loss per share $1.59.  Full Article

Agios posts Q2 loss per share $1.78‍​
Tuesday, 8 Aug 2017 07:01am EDT 

Aug 8 (Reuters) - Agios Pharmaceuticals Inc :Agios reports second quarter 2017 financial results.Agios Pharmaceuticals Inc - ‍collaboration revenue was $11.3 million for quarter ended June 30, 2017, compared to $7.0 million for comparable period in 2016​.Agios Pharmaceuticals Inc - ‍expects to submit an NDA (new drug application) to U.S. FDA for ivosidenib for IDH1M positive r/r AML by end of 2017​.Agios Pharmaceuticals Inc - ‍expects to submit ind application for AG-270, development candidate targeting mtap-deleted tumors, by end of 2017​.Agios Pharma - ‍expects cash, cash equivalents as of June 30, 2017, will enable company to fund its anticipated through at least end of 2019​.Agios Pharmaceuticals Inc qtrly loss per share $1.78‍​.Q2 earnings per share view $-1.56, revenue view $9.6 million -- Thomson Reuters I/B/E/S.  Full Article

Agios Pharma says FDA approves Idhifa for treating relapsed/refractory Acute Myeloid Leukemia
Tuesday, 1 Aug 2017 11:30am EDT 

Aug 1 (Reuters) - Agios Pharmaceuticals Inc :FDA grants approval of Idhifa, the first oral targeted therapy for adult patients with relapsed/refractory acute myeloid leukemia and an IDH2 mutation.  Full Article

Agios names former Celgene executive Jacqualyn Fouse as next CEO

Agios Pharmaceuticals Inc on Tuesday said former Celgene Corp executive Jacqualyn Fouse would be its next chief executive officer, replacing longtime CEO David Schenkein.